Research projects

  • Development and validation of immunoassays for novel immunotherapy drugs such as KEYTRUDA (pembrolizumab), OPDIVO (nivolumab) and YERVOY (ipilimumab), for monitoring drug levels in patients with lung cancer and malignant melanoma.
  • Developing assays for measuring different monoclonal antibodies used in the treatment of patients with autoimmune diseases. These assays are used in the clinical routine and in several ongoing clinical trials.
  • Detection of antibodies to transglutaminase in the HUNT4-cohort using an in-house dual label assay in collaborative study “Coeliac disease in HUNT”.
  • Late effects after testicular cancer; thyroid and kidney function, in collaboration with National Advisory Unit on Late Effects after Cancer Treatment.
  • Screening for patient antibodies to HH1, a novel antibody-based drug used in lymphoma clinical trials (Lymrit).
  • Part of the collaboration study “Hallmarks in lung cancer”; validating different markers for potential development of assays clinically useful indaily practice.
  • Investigating the potential effect of combinatorial treatment of melanoma with PLX4032 (vemurafenib) and HER antibodies (in vitro studies).
  • Validating immunoassays for human epidermal growth factor receptors 2, 3 and 4 as tumour markers for HER2 positive breast cancer.
 
Page visits: 1675